TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12065987
Drug: Nonsurgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatments for intervertebral disc herniation
Study: 12065987
Drug: Nonsurgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatments for spinal stenosis
Study: 12065987
Drug: Nonsurgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatments for degenerative spondylolisthesis
Study: 6831838
Drug: Aminophylline administered
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline administered intravenously prior to, during and/or after fatigue
Study: 14678373
Drug: Ro 115-1240
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 115-1240 (1.5 mg twice daily for 2 or 4 weeks)
Study: 215795
Drug: Pivmecillinam (PMPC)
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam (PMPC) 200 mg per day
Study: 215795
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (NA) 2000 mg per day
Study: 25423571
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (30 g glucose and 3 g 3‐O‐methylglucose)
Study: 21227548
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (non-titrated, 9.5 mg/day for 3 months)
Study: 21227548
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (titrated, 4.6 mg/day for 1 month followed by 9.5 mg/day for 2 months)
Study: 21227548
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (6-12 mg/day for 3 months)
Study: 16112255
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate vaccine (MCC-TT)
Study: 15131544
Drug: abciximab (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (24-hour or 48-hour infusion)
Study: 12551868
Drug: abciximab (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (48-hour infusion)
Study: 11239100
Drug: Court-ordered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Court-ordered treatment (78 participants)
Study: 9404911
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel followed by oxytocin
Study: 2892545
Drug: Etintidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine (400 mg)
Study: 30499485
Drug: NSAID-based anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-based anti-inflammatory therapy
Study: 27538683
Drug: Nebulized VRP700
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized VRP700 (1.0 mg/kg)
Study: 22339945
Drug: Zirconia copings
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia copings generated with the Lava system (group L)
Study: 20372053
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (9 microg of haemagglutinin per strain)
Study: 20372053
Drug: Intramuscular control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular control vaccine (15 microg haemagglutinin per strain)
Study: 7759396
Drug: Gentamicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.5 mg/kg/day, once daily
Study: 7759396
Drug: Gentamicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.5 mg/kg/day, thrice daily
Study: 4578364
Drug: Clofibrate 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate 1.6 g daily
Study: 4578364
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules (300-350 mg)
Study: 26619553
Drug: Syndrome differentiation
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syndrome differentiation treatment group
Study: 26619553
Drug: Disease differentiation
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease differentiation treatment group
Study: 7497776
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (0.9%)
Study: 23605469
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of olanzapine 10 mg
Study: 23605469
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of olanzapine 10 mg
Study: 23605469
Drug: Test vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test vs. Reference formulation
Study: 17267292
Drug: 1.75 mg
Normalized name: glyburide 1.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mg midazolam
Study: 17267292
Drug: 5.25 mg
Normalized name: lysine 5.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25 mg midazolam
Study: 15561831
Drug: Levofloxacin at
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin at 750 mg once daily plus metronidazole at 500 mg every 8 hours
Study: 15561831
Drug: Levofloxacin at
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin at 750 mg once daily plus metronidazole at 1,500 mg every 24 hours
Study: 15561831
Drug: Levofloxacin at
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin at 750 mg once daily plus metronidazole at 1,000 mg every 24 hours
Study: 9223063
Drug: THA 25
Normalized name: Xyntha 250 UNT/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: THA 25 mg
Study: 9223063
Drug: THA 50
Normalized name: Xyntha 500 UNT/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: THA 50 mg
Study: 8273571
Drug: Azapropazone (APZ)
Normalized name: azapropazone
DrugBank: Azapropazone (DB07402)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone (APZ) 600 mg b.i.d.
Study: 8273571
Drug: Indomethacin (IND)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IND) 50 mg t.i.d.
Study: 8273571
Drug: Naproxen (NAP)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (NAP) 500 mg b.i.d.
Study: 8273571
Drug: Piroxicam (PIR)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam (PIR) 20 mg qq.d.
Study: 21392067
Drug: PF-734200 20
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-734200 20 mg/day
Study: 21392067
Drug: PF-734200 30
Normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-734200 30 mg/day
Study: 17223873
Drug: Topical methylaminolaevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methylaminolaevulinate (MAL) photodynamic therapy (PDT)
Study: 17223873
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% fluorouracil (5‐FU) cream
Study: 11394510
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg x kg(‐1) (PM; n = 13)
Study: 7880512
Drug: Subarachnoid bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid bupivacaine blockade (12.5 mg)
Study: 7880512
Drug: Intramuscular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline (control)
Study: 7880512
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (control)
Study: 3367388
Drug: 252Cf therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 252Cf therapy
Study: 3367388
Drug: 137Cs therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 137Cs therapy
Study: 29333561
Drug: Venetoclax (10-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (10-500 mg single doses and 30-600 mg multiple doses)
Study: 25088029
Drug: Polyphenol-enriched protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-enriched protein powder (PSPC) 40 g/day for 17 days
Study: 22913893
Drug: Proactive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive intervention based on single-pill amlodipine/atorvastatin (SPAA) 5/10 to 10/20 mg
Study: 12852710
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Study: 12852710
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of PLT 3514 emulsion (1.5 g GLA + 1 g EPA)
Study: 12852710
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of PLT 3514 emulsion (7.5 g GLA + 5 g EPA)
Study: 10390662
Drug: Dimenhydrinate (62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (62 mg IV after induction, repeated three times during 48 hours)
Study: 1802054
Drug: Treatment regimes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimes without bone grafting
Study: 1802054
Drug: Treatment regimes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimes including bone grafting at 10 years of age
Study: 6404440
Drug: Heat inactivated
Normalized name: Heat inactivated convalescent plasma
DrugBank: V-SARS (DB15812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat inactivated hepatitis B virus vaccine (3 micrograms HBsAg)
Study: 6404440
Drug: Heat inactivated
Normalized name: Heat inactivated convalescent plasma
DrugBank: V-SARS (DB15812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat inactivated hepatitis B virus vaccine
Study: 29879143
Drug: Ipilimumab (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (0.1, 1, 3, or 5 mg/kg) administered every 28 days for 2 or 4 doses
Study: 27379733
Drug: Other antidiabetic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidiabetic therapies
Study: 19098657
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Cefotaxime at the moment of gallbladder rupture, followed by 2 more doses at intervals of 8 hours in the immediate postoperative period
Study: 12848773
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin twice daily for 3 days
Study: 12848773
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin with oral clarithromycin
Study: 1868679
Drug: Temazepam 5
Normalized name: temazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 5 mg
Study: 7079903
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15-(S)-15-methyl-PGF2 alpha
Study: 7079903
Drug: Continuous intra-uterine
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous intra-uterine extra-amniotic infusion of 15-(S)-15-methyl-PGF2 alpha
Study: 30789856
Drug: Ilaprazole 5
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 5 mg
Study: 28434798
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (DE) (77Gy/35 fractions) to hypoxic volumes (HV)
Study: 27146475
Drug: Group Person‐Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Person‐Based Cognitive Therapy (PBCT) and Treatment As Usual (TAU)
Study: 27146475
Drug: Group Person‐Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Person‐Based Cognitive Therapy (PBCT)
Study: 24529582
Drug: Sertraline 25
Normalized name: sertraline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 25 mg/day for 1 week followed by 50 mg/day for 3 months
Study: 24529582
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy (BT) for 3 months
Study: 19179739
Drug: Cord serum
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord serum screening test measuring total serum IgE, Der p1, Blo t5, and g IFN levels
Study: 15337334
Drug: Concordance Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordance Therapy
Study: 16779878
Drug: No ointment
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ointment
Study: 16779878
Drug: Paraffin ointment
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin ointment
Study: 10968910
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with aspirin and heparin
Study: 2057034
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 20 mg per day)
Study: 6733393
Drug: d-amphetamine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 7.5 mg
Study: 6733393
Drug: d-amphetamine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 12.5 mg
Study: 26135372
Drug: Resistive underwater
Normalized name: OCTINOXATE 3.75 g in 50 mL / OCTISALATE 2.5 g in 50 mL / TITANIUM DIOXIDE 1.75 g in 50 mL TOPICAL CREAM [WKND UNDERWATER SUN SCREEN 50ML]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive underwater exercises and interferential current therapy
Study: 26135372
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy program (Control)
Study: 22009840
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment through the paravertebral muscle approach
Study: 26386827
Drug: Buspirone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (up to 60 mg/day)
Study: 21530058
Drug: Metformin (1700‐3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700‐3000 mg/day)
Study: 19117084
Drug: Barley starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley starch syrup
Study: 9421774
Drug: 48 h
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 h change of infusion systems
Study: 9421774
Drug: 96 h
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 h change of infusion systems
Study: 9421774
Drug: In-line infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-line infusion filters
Study: 8214738
Drug: Endotracheal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal lidocaine administration
Study: 8214738
Drug: Deep endobronchial
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep endobronchial lidocaine administration
Study: 3307601
Drug: DDP (Cisplatinum)
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP (Cisplatinum) 100 mg/m2 administered on day 1
Study: 3307601
Drug: DDP-Etoposide (DDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP-Etoposide (DDP 100 mg/m2 on day 4 and Etoposide 100 mg/m2 per os on days 1 to 5)
Study: 29577247
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a water-in-oil emulsion with pH 4
Study: 29577247
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a water-in-oil emulsion with pH 5.8
Study: 23259262
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of scalp and body acupuncture by stages (specific acupoints selected based on disease stage).
Study: 23259262
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of scalp and body acupuncture by stages.
Study: 20855284
Drug: Bufeishenqingre decoction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufeishenqingre decoction, administered twice a day for one month.
Study: 20855284
Drug: Theophylline sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline sustained-release capsules, 100 mg administered twice a day for one month.
Study: 16172456
Drug: ABI‐007 260
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI‐007 260 mg/m² intravenously without premedication
Study: 16172456
Drug: Standard paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard paclitaxel 175 mg/m² intravenously with premedication
Study: 12609940
Drug: 100 000
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 000 IU oral vitamin D3 (cholecalciferol) supplementation every four months
Study: 1657078
Drug: CVM (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVM (carboplatin 300 mg/m2, vinblastine 6 mg/m2, methotrexate 30 mg/m2, intravenously every 4 weeks)
Study: 1657078
Drug: ACE (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE (doxorubicin 40 mg/m2, cyclophosphamide 600 mg/m2, etoposide 100 mg/m2, intravenously day 1-3, every 3 weeks)
Study: 30729881
Drug: Problem-solving-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving-based intervention focused on caregiver medication management
Study: 26850307
Drug: BUD/FM 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM 160/4.5 μg plus as-needed BUD/FM (SMART group, n=15)
Study: 26850307
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 μg plus as-needed procaterol (FF/VI group, n=15)
Study: 16712981
Drug: Validation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validation Therapy (VT)
Study: 29284607
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (Control)
Study: 12518931
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 40 mg/day, with furosemide if needed)
Study: 12518931
Drug: Lacidipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (up to 8 mg/day)
Study: 10520979
Drug: Clonazepam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.25 to 4.0 mg in 2 divided doses)
Study: 10520979
Drug: Clonazepam (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (during tapering)
Study: 7741289
Drug: Passive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive treatment 0.0 mA for 2 h (0 mA.min)
Study: 27666126
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg for 5 days
Study: 27666126
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg plus hydrochlorothiazide 25 mg for 5 days
Study: 27666126
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg plus torasemide 5 mg for 5 days
Study: 27666126
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg for 4 days
Study: 27666126
Drug: Torasemide 5
Normalized name: Torasemide 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 5 mg for 4 days
Study: 23589316
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (Control group, N=31)
Study: 23589316
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy drugs and intraperitoneal perfusion of verapamil (Combined treatment group, N=41)
Study: 23589316
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (N=41)
Study: 8245520
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (1770 pfu/dose)
Study: 8245520
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (400‐500 pfu/dose)
Study: 8245520
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (80‐160 pfu/dose)
Study: 29023192
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with Methylene Blue dye (0.01%) and laser therapy (660 nm, 30 mW, 8 sec, 6 J/cm2, beam area of 0.04 mm2), three times per week for 10 sessions
Study: 26896305
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 25‐30 min of aerobic exercise
Study: 26896305
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50‐60 min of aerobic exercise
Study: 26896305
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of 50‐60 min of aerobic and resistance exercise